Levetiracetam
Product Images NDC 67046-421

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 67046-421). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2cd73426-figure-01 (2cd73426 Figure 01)

Chemical structure diagram of the active ingredient Levetiracetam showing its molecular formula with a pyrrolidone ring attached to an ethyl group and an amide functional group.*

FDA Label Image

2cd73426-figure-02 (2cd73426 Figure 02)

A bar graph comparing the percentage of patients by treatment group: placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The x-axis shows the treatment groups with sample sizes, and the y-axis shows the percentage of patients ranging from 0% to 45%.*

FDA Label Image

2cd73426-figure-03 (2cd73426 Figure 03)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart shows increasing patient percentages with higher Levetiracetam doses, labeled with respective patient numbers in each group.*

FDA Label Image

2cd73426-figure-04 (2cd73426 Figure 04)

A bar graph comparing the percentage of patients between placebo (14.4%, N=104) and Levetiracetam 3000 mg/day (39.4%, N=180). The y-axis represents the percentage of patients from 0% to 45%, showing a higher percentage in the Levetiracetam group.*

FDA Label Image

2cd73426-figure-05 (2cd73426 Figure 05)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 44.6%, indicating a higher percentage for Levetiracetam.*

FDA Label Image

2cd73426-figure-06 (2cd73426 Figure 06)

A bar graph comparing the percentage of patients between Placebo (N=84) and Levetiracetam (N=79). The vertical axis shows the percentage from 0% to 100%. Levetiracetam shows a higher percentage (72.2%) compared to Placebo (45.2%).*

FDA Label Image

2cd73426-figure-07 (2cd73426 Figure 07)

A text panel presenting a formula for calculating total daily dose in mL/day for Levetiracetam. The formula is given as Daily dose (mg/kg/day) multiplied by patient weight (kg), divided by 100 mg/mL.*

FDA Label Image

2cd73426-figure-08 (2cd73426 Figure 08)

A drug facts panel displaying the formula to calculate creatinine clearance (CLcr) based on age, weight, and serum creatinine values, with an adjustment factor for female patients.*

FDA Label Image

2cd73426-figure-10 (2cd73426 Figure 10)

Label for Levetiracetam 500 mg tablets, bottle of 30, by Contract Pharmacy Services-PA. The label includes storage instructions, the lot number 4141576, and an expiration date of 03/05/16. It notes that each film-coated tablet contains 500 mg levetiracetam. The product is prescription only with NDC 67046-421-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.